Evidence
Biomaterials. 2024 Feb 8;306:122506. doi: 10.1016/j.biomaterials.2024.122506. Online ahead of print.
ABSTRACT
The most common chronic liver illness, non-alcoholic fatty liver disease (NAFLD), refers to a range of abnormalities of the liver with varying degrees of steatosis. When the clinical symptoms including liver damage, inflammation, and fibrosis, are added to the initial steatosis, NAFLD becomes non-alcoholic steatohepatitis (NASH), the problematic and severe stage. The diagnosis of NASH at the right time could therefore effectively prevent deterioration of the disease. Considering that platelets (PLTs) could migrate to the sites of inflamed liver sinusoids with oxidative stress during the development of NASH, we purified the PLTs from fresh blood and engineered their surface with hydrogen peroxide (H2O2) responsive fluorescent probe (5-DP) through lipid fusion. The engineered PLT-DPs were recruited and trapped in the inflammation foci of the liver with NASH through interaction with the extracellular matrix, including hyaluronan and Kupffer cells. Additionally, the fluorescence of 5-DP on the surface of PLT-DP was significantly enhanced upon reacting with the elevated level of H2O2 in the NASH liver. Thus, PLT-DP has great promise for NASH fluorescence imaging with high selectivity and sensitivity.
PMID:38354517 | DOI:10.1016/j.biomaterials.2024.122506
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
🌐 90 Days
VR Related Evidence Matrix
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An…
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Bacteroides and NAFLD: pathophysiology and therapy
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease
- Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease
- The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis
- Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
- Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease
- Role of resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, in managing non-alcoholic steatohepatitis: a systematic review and meta-analysis
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARalpha and suppressing HIF1
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Terf2ip deficiency accelerate non-alcoholic steatohepatitis through regulating lipophagy and fatty acid oxidation via Sirt1/ AMPK pathway
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Integrative analysis identifies oxidative stress biomarkers in non-alcoholic fatty liver disease via machine learning and weighted gene co-expression network analysis
- 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine-choline-deficient diet and Western diet mouse models
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines
Evidence Blueprint
Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
🌐 365 Days
VR Related Evidence Matrix
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- Mitochondrial- and NOX4-dependent antioxidant defence mitigates progression to non-alcoholic steatohepatitis in obesity
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Validation of computed tomography as a diagnostic tool in guinea pigs with non-alcoholic fatty liver disease
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- A Markov model of fibrosis development in Non-Alcoholic Fatty Liver Disease predicts fibrosis progression in clinical cohorts
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver
- Miniseries: Established pharmacological targets for NASHFXR agonists in NASH treatment
- Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report
- Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An…
- Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in Mice
- Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis with liver fibrosis as predictors of new-onset Diabetes Mellitus in People living with HIV: A Longitudinal Cohort Study
- Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
- Research progress on the histological scoring system for nonalcoholic fatty liver disease
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metabolism
- Glucosinolates Extracts from Brassica juncea Ameliorate HFD-Induced Non-Alcoholic Steatohepatitis
- Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- Identification of pyroptosis-related gene signature in nonalcoholic steatohepatitis
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
- Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Impact of fibrosis on liver-related event incidence in non-alcoholic fatty liver disease: A multicenter observational study
- Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients
- NAFLD and NASH: etiology, targets and emerging therapies
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1
- Mitigation of non-alcoholic steatohepatitis via recombinant Orosomucoid 2, an acute phase protein modulating the Erk1/2-PPARγ-Cd36 pathway
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts
- Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Bioinformatics analysis and machine learning approach applied to the identification of novel key genes involved in non-alcoholic fatty liver disease
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis